Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab for CRS and ICANS After CAR-T in Multiple Myeloma
NCT07106671Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2025; status: recruiting.
02
Drugs
siltuximab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT07106671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106671.